AU2002351495A1 - Neutrokine-alpha and neutrokine-alpha splice variant - Google Patents

Neutrokine-alpha and neutrokine-alpha splice variant

Info

Publication number
AU2002351495A1
AU2002351495A1 AU2002351495A AU2002351495A AU2002351495A1 AU 2002351495 A1 AU2002351495 A1 AU 2002351495A1 AU 2002351495 A AU2002351495 A AU 2002351495A AU 2002351495 A AU2002351495 A AU 2002351495A AU 2002351495 A1 AU2002351495 A1 AU 2002351495A1
Authority
AU
Australia
Prior art keywords
neutrokine
alpha
splice variant
variant
alpha splice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002351495A
Inventor
Reinhard Ebner
Michael W. Laird
Jian Ni
Craig A. Rosen
Stephen Ullrich
Guo-Liang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU2002351495A1 publication Critical patent/AU2002351495A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU2002351495A 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant Abandoned AU2002351495A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US32950801P 2001-10-17 2001-10-17
US60/329,508 2001-10-17
US32974701P 2001-10-18 2001-10-18
US60/329,747 2001-10-18
US33083501P 2001-10-31 2001-10-31
US60/330,835 2001-10-31
US33147801P 2001-11-16 2001-11-16
US60/331,478 2001-11-16
US33672601P 2001-12-07 2001-12-07
US60/336,726 2001-12-07
US36854802P 2002-04-01 2002-04-01
US60/368,548 2002-04-01
PCT/US2002/032910 WO2003033658A2 (en) 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant

Publications (1)

Publication Number Publication Date
AU2002351495A1 true AU2002351495A1 (en) 2003-04-28

Family

ID=27559746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002351495A Abandoned AU2002351495A1 (en) 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant

Country Status (4)

Country Link
EP (1) EP1507793A4 (en)
AU (1) AU2002351495A1 (en)
CA (1) CA2476675A1 (en)
WO (1) WO2003033658A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
PT2275449T (en) 2000-06-16 2016-12-27 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
EP2332563A3 (en) 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
ES2618543T3 (en) 2005-11-23 2017-06-21 Genentech, Inc. Methods and compositions related to B lymphocyte assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
KR20140085544A (en) 2006-05-30 2014-07-07 제넨테크, 인크. Antibodies and immunoconjugates and uses therefor
ES2666170T3 (en) 2007-10-30 2018-05-03 Genentech, Inc. Purification of antibodies by cation exchange chromatography
KR102196883B1 (en) 2008-08-14 2020-12-30 제넨테크, 인크. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
EP2684570A1 (en) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
JP5937059B2 (en) 2010-03-22 2016-06-22 ジェネンテック， インコーポレイテッド Compositions and methods useful for stabilizing protein-containing formulations
CN102958538A (en) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 Compositions and methods useful for reducing the viscosity of protein-containing formulations
MX339666B (en) 2010-06-24 2016-06-03 Genentech Inc * Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations.
SG11201403437TA (en) 2011-12-22 2014-07-30 Genentech Inc Ion exchange membrane chromatography
AU2020254582A1 (en) 2019-04-01 2021-09-30 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN110176272B (en) * 2019-04-18 2021-05-18 浙江工业大学 Protein disulfide bond prediction method based on multi-sequence association information

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503263A (en) * 1996-10-25 2001-03-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Neutrokine α
EP1309718A4 (en) * 2000-08-15 2004-08-25 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant

Also Published As

Publication number Publication date
EP1507793A4 (en) 2006-02-01
EP1507793A2 (en) 2005-02-23
CA2476675A1 (en) 2003-04-24
WO2003033658A3 (en) 2004-05-27
WO2003033658A2 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
AU2002323145A1 (en) Optical materials and optical devices
AU2002351495A1 (en) Neutrokine-alpha and neutrokine-alpha splice variant
AU2002315389A1 (en) Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
AU2002234643A1 (en) Amphoteric liposomes and the use thereof
EP1157110A4 (en) Neutrokine-alpha and neutrokine-alpha splice variant
AU2001288260A1 (en) Neutrokine-alpha and neutrokine-alpha splice variant
AU2002315388A1 (en) Novel phenylamino-pyrimidines and uses thereof
AU2002305523A1 (en) Dioxanes and uses thereof
AU2002211717A1 (en) Stresscopins and their uses
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2002343724A1 (en) Adhesive and use thereof
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2002227019A1 (en) Cashcalling and voicemining system
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU2002256556A1 (en) Sea-trosy and related methods
AU2002354083A1 (en) Cylinder-lock and flat-key combination
AU2002354710A1 (en) Q9ul33/q9nzz4 and q9h5p3 splice variants
AU2002244856A1 (en) Splice variant
AU2002349129A1 (en) Lipid structures and uses thereof
AU2002240498A1 (en) Protected deoxyadenosines and deoxyguanosines
AU2002345562A1 (en) Human tachykinin-related splice variants and compositions thereof
AU2002323876A1 (en) Splice protection sleeve
AU2002228426A1 (en) Neurotonin and use thereof
HK1046707A1 (en) Neutrokine-alpha and neutrokine-alpha splice variant

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase